PHC Corporation's biomedical division is planning to showcase its prototype of its novel cell expansion system: LiCellGrow, at ISCT Europe.
The event, which will be held in Gothenburg, Sweden this year, brings together those in the cell and gene therapy space, allowing them to network and catch up on the latest industry innovations.
LiCellGrow is designed to allow pharmaceutical companies to continuously monitor metabolic changes in cells in real time.
This allows the to adjust cell cultures rapidly to optimise cell growth conditions, potentially leading to higher product yields.
The technology endeavours to enhance the availability of cell and gene therapy (CGT) products by expediting the cell manufacturing process.
Cell and gene therapies have been gaining traction in the pharmaceutical industry in recent years, as their efficacy in a number of difficult to treat diseases is being uncovered in both preclinical and clinical studies.
As the stability and quality of such cells is essential for the efficacy and safety of CGTs, quality evaluation methods have been put in place — which unfortunately currently impact process efficiency and yield.
PHC plans to introduce LiCellGrow to enable more efficient and stable manufacture of CGT products through in-line monitoring techology, which focuses on cell metabolite levels in the culture.
The system will also feature single-use culture bags, which allows the maintenance of sterility.